{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-103053","form_type":"8-K","ticker":"DNTH","cik":"0001690585","company_name":"Dianthus Therapeutics, Inc. /DE/","filed_at":"2026-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.901741+00:00","generated_at":"2026-05-15T13:38:43.878322+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Dianthus Therapeutics raises ~$673.5M in public offering of common stock and pre-funded warrants","bullets":["Offering of 7,313,582 shares at $81.00/share and pre-funded warrants for 402,468 shares at $80.999/share.","Underwriters exercised in full option to purchase additional 1,157,407 shares on March 11, 2026.","Net proceeds expected to be approximately $673.5 million after underwriting discounts and expenses.","Offering expected to close March 12, 2026; securities offered under shelf registration statement."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-103053","json":"https://secwatch.observer/filing/0001193125-26-103053.json","markdown":"https://secwatch.observer/filing/0001193125-26-103053.md","text":"https://secwatch.observer/filing/0001193125-26-103053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1690585/000119312526103053/0001193125-26-103053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1690585/000119312526103053/d43448d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T13:38:43.878322+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e3ef4e92da2a600c535001650bbc4b70f92eae3d","claim":"Dianthus Therapeutics, Inc. /DE/ entered into Underwriting Agreement with Jefferies LLC, TD Securities (USA) LLC, Evercore Group L.L.C., Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC, as the representatives of the underwriters valued at approximately $673.5 million (effective 2026-03-10).","evidence_excerpt":"On March 10, 2026, Dianthus Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (“Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, Evercore Group L.L.C., Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC, as the representatives of the underwriters named therein (the “Underwriters”), to issue and sell 7,313,582 shares of the Company’s common stock at a public offering price of $81.00 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 402,468 shares of the Company’s common stock (the “Pre-Funded Warrants”) at a public offering price of $80.999 per share, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each Pre-Funded Warrant (the “Offering”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1690585/000119312526103053/0001193125-26-103053-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Jefferies LLC, TD Securities (USA) LLC, Evercore Group L.L.C., Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC, as the representatives of the underwriters"},{"label":"Value","value":"approximately $673.5 million"},{"label":"Effective","value":"2026-03-10"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}